Evidence map›Paper›PMID 35550001›Full record

ReviewPathogens and global health2023

Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design.

Chin Peng Lim, Boon Hui Kok, Hui Ting Lim, Candy Chuah, Badarulhisam Abdul Rahman, Abu Bakar Abdul Majeed, Michelle Wykes, Chiuan Herng Leow, Chiuan Yee Leow

Open access · greenAbstract readReview
In one paragraph

Review in Pathogens and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Chin Peng LimSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.
Boon Hui KokInstitute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor, Malaysia.
Hui Ting LimInstitute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor, Malaysia.
Candy ChuahFaculty of Health Sciences, Universiti Teknologi MARA, Penang, Malaysia.
Badarulhisam Abdul RahmanPharmaniaga Berhad, Kawasan Perindustrian Bukit Raja Selatan, Shah Alam, Malaysia.
Abu Bakar Abdul MajeedFaculty of Pharmacy, Universiti Teknologi MARA, Bandar Puncak Alam, Malaysia.
Michelle WykesMolecular Immunology Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Chiuan Herng LeowInstitute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor, Malaysia.ORCID 0000-0003-0849-428X
Chiuan Yee LeowSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.
Universiti Sains Malaysia · MYUniversiti Teknologi MARA · MYQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has globally devastated public health, the economies of many countries and quality of life universally. The recent emergence of immune-escaped variants and scenario of vaccinated individuals being infected has raised the global concerns about the effectiveness of the current available vaccines in transmission control and disease prevention. Given the high rate mutation of SARS-CoV-2, an efficacious vaccine targeting against multiple variants that contains virus-specific epitopes is desperately needed. An immunoinformatics approach is gaining traction in vaccine design and development due to the significant reduction in time and cost of immunogenicity studies and increasing reliability of the generated results. It can underpin the development of novel therapeutic methods and accelerate the design and production of peptide vaccines for infectious diseases. Structural proteins, particularly spike protein (S), along with other proteins have been studied intensively as promising coronavirus vaccine targets. Numbers of promising online immunological databases, tools and web servers have widely been employed for the design and development of next generation COVID-19 vaccines. This review highlights the role of immunoinformatics in identifying immunogenic peptides as potential vaccine targets, involving databases, and prediction and characterization of epitopes which can be harnessed for designing future coronavirus vaccines.

Indexed as

COVID-19Viral VaccinesCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMolecular Docking SimulationQuality of LifeReproducibility of ResultsSARS-CoV-2COVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteViral Vaccinescharacterizationdatabaseepitope predictionHuman coronavirusimmunoinformaticspeptide vaccinevaccine target

Identifiers

PMID35550001
PMCPMC9970233
OpenAlexW4280623705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.